These results further confirmed more than 40% of HCC patients presented elevated anti-GNAS autoantibody levels in sera at, or prior to the diagnosis of HCC, suggesting that GNAS might be an early marker of transformation and the corresponding autoantibody may be a potential biomarker for early detection of HCC. The gene discussed is GNAS; the disease is hepatocellular carcinoma.